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Phosphoglucomutase 1 (PGM1) deficiency is a rare genetic disorder that 
affects  glycogen metabolism, glycolysis, as well as one of the most 
important biological processes namely glycosylation. Previously known as 
GSD XIV, it was recently re-classified as a congenital disorder of 
glycosylation, PGM1-CDG. Owing to the important biochemical positioning 
of the affected enzyme, PGM1-CDG usually manifests as a multisystem 
disease. Due to the variety of clinical features of the many different CDG, 
the diagnosis can be difficult. Unlike most other CDG, PGM1-CDG has an 
effective treatment option, D-galactose, which has shown to improve 
many of the patients’ symptoms. Therefore, early diagnosis and treatment 
in these patients are crucial. In this paper, our group of international 
experts suggests diagnostic, follow-up and management guidelines for 
PGM1-CDG. The guidelines are based on the best available evidence-
based data and experts' opinions aiming to provide a practical resource 
for health care providers to facilitate early diagnosis and appropriate 





Congenital disorder of glycosylation, Phosphoglucomutase 1 deficiency, 
PGM1-CDG, Management guidelines. 
Abbreviations 
PGM1-CDG Phosphoglucomutase 1 deficiency, CDG congenital disorders of glycosylation, GSD glycogen 
storage disorder, SIGN Scottish Intercollegiate Guidelines Network, EEG electroencephalogram, MRI 
magnetic resonance imaging, CNS central nervous system, FSH follicle-stimulating hormone, TBG 
thyroxin-binding globulin, IGFBP-3 insulin-like growth factor-binding protein 3, AST aspartate 
aminotransferase, ALT alanine aminotransferase, CK creatine kinase, TPCRS Tulane PGM1-CDG Rating 
Scale, EMG electromyography, NCS nerve conduction studies, Tf serum transferrin, TIEF transferrin 
isoelectric focusing, CE capillary electrophoresis, HPLC High-Performance Liquid Chromatography, 




PGM1-CDG (OMIM 614921), previously known as congenital disorder of 
glycosylation 1T (CDG1T) and glycogen storage disorder GSD XIV, is a rare 
autosomal recessive disorder caused by PGM1 (phosphoglucomutase 1) 
enzyme deficiency. This disorder was initially reported in two patients 
with diverse presentations. Thomson 19631 reported a child that 
presented with a cardiac conduction defect and skeletal myopathy. In 
contrast, Sugie 19882 identified it in an infant with recurrent vomiting, 
failure to thrive and hepatopathy.  
PGM1 deficiency is caused by mutations in PGM1, which encodes PGM1, 
the predominant isoform of the phosphoglucomutase family.  In most cell 
types, it represents around 90 % of total PGM activity and is expressed 
ubiquitously in different tissues. In contrast, PGM1 is absent in red blood 
cells, where PGM2 is the predominant isoform (Tegtmeyer 2014).  
PGM1 catalyzes the interconversion of glucose 1-phosphate and glucose 
6-phosphate, and is involved in several crucial metabolic pathways such as 
glycolysis, glycogenolysis, glycogenesis and, indirectly, N-linked 
glycosylation (Quick 1974, Tegtmeyer 2014) 3. Therefore, it is not 
surprising that this disorder was first categorized as a GSD (Stojkovic 2009)  
4 and only later as a CDG (Timal 2012) 5. 
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This disorder presents as two major phenotypes: a primary myopathic one 
and a multisystem one. The latter involves congenital malformations (cleft 
palate, bifid uvula, cardiac valves malformations, anal atresia, and 
vertebral anomalies), variable endocrine and hematological abnormalities, 
cardiac, muscle and hepatic involvement (Morava 2015) 6. The prevalence 
of PGM1-CDG is unknown.  Fifty seven molecularly confirmed PGM1-CDG 
patients have been reported from different ethnicities. 
PGM1-CDG is one of the few inborn errors of metabolism with  an 
effective treatment in the form of D-galactose (Tegtmeyer 2014). This 
monosaccharide can restart the glycosylation in PGM1-CDG patients by 
replenishing the depleted pools of UDP-glucose and UDP-galactose, 
necessary for the N-glycosylation (Radenkovic 2019), improving several  
symptoms. Early diagnosis and administration of D-galactose is thus 
essential for these patients.  
To facilitate the diagnosis and management of PGM1-CDG, we offer 
detailed guidelines specifically focusing on the affected organ systems, 
diagnostic tools and treatment with D-galactose. 
Methodology  
An international group of experts in disorders of glycosylation reviewed 
the evidence base and developed management guidelines.  A PubMed 
database search was performed from the date of the first clinical 
description till December 2019 using the following terms: carbohydrate-
deficient glycoprotein syndrome OR congenital disorder of glycosylation 
type It OR PGM1-CDG OR phosphoglucomutase 1 deficiency. Neurological, 
ophthalmologic, cardiac, endocrine, hematological, immunological, 
gastrointestinal, hepatic, and musculoskeletal systems were reviewed. 
Next, a consensus was developed in each area of diagnosis, treatment, 
and management. For the most part, the evidence and resulting 
recommendations are considered experts’ opinions because additional 
levels of evidence were not available in the literature.  Evidence levels 
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were classified in accordance with the Scottish Intercollegiate Guidelines 




Thirty five articles were found through PubMed database search:13 case 
reports, 9 case series, 7 diagnostic papers and 6 reviews. A review of the 
57 molecularly confirmed PGM1-CDG patients and affected systems are 
summarized in supplementary table 1, and the clinical presentations  and 




SYSTEMS SUMMARIES AND STATEMENTS  
CONGENITAL MALFORMATIONS 
Of 57 patients with PGM1-CDG reported to date, cleft palate was the most 
commonly reported anomaly (n=28) followed by bifid uvula (n=25), and 
Pierre-Robin sequence (n=15). The term “first branchial arch syndrome” 
(Pérez 20137) was also used to describe the findings of a patient later 
reported as having Pierre-Robin sequence (Wong 20168). In the largest 
cohort published to date, the presence of either bifid uvula, cleft palate or 
Pierre-Robin sequence was identified in 23/27 patients (Wong 2016). 
Other findings occasionally reported include prominent forehead, small 
face and depressed nasal bridge (Küçükçongar 20159), hypertelorism, 
short neck, retrognathia, smooth philtrum and low set ears (Zeevaert 
201610), dysmorphic ears, preauricular tissue (Schrapers 201611), 
undescended testes (Nolting 201712), foreshortened esophagus (Preisler 
201713), anal atresia, and a missing lumbar vertebra (Wong 2016). 
 
 
7 Pérez B, Medrano C, Ecay MJ, Ruiz-Sala P, Martínez-Pardo M, Ugarte M, Pérez-Cerdá C. 
A novel congenital disorder of glycosylation type without central nervous system involvement caused by 
mutations in the phosphoglucomutase 1 gene.J Inherit Metab Dis. 2013 May;36(3):535-42. doi: 
10.1007/s10545-012-9525-7. Epub 2012 Sep 14. 
8 Wong SY, Beamer LJ, Gadomski T, Honzik T, Mohamed M, Wortmann SB, Brocke Holmefjord KS, Mork 
M, Bowling F, Sykut-Cegielska J, Koch D, Ackermann A, Stanley CA, Rymen D, Zeharia A, Al-Sayed M, 
Marquardt T, Jaeken J, Lefeber D, Conrad DF, Kozicz T, Morava E. Defining the Phenotype and Assessing 
Severity in Phosphoglucomutase-1 Deficiency.J Pediatr. 2016 Aug; 175:130-136.e8. doi: 
10.1016/j.jpeds.2016.04.021. Epub 2016 May 17 
9   Küçükçongar A, Tümer L, Ezgü FS, Kasapkara ÇS, Jaeken J, Matthijs G, Rymen D, Dalgiç B, Bıdecı A, 
Hasanoğlu A. A case with rare type of congenital disorder of glycosylation: PGM1-CDG. Genet Couns. 
2015;26(1):87-90 
10 Zeevaert R, Scalais E, Muino Mosquera L, De Meirleir L, De Beaufort C, Witsch M, Jaeken J, De 
Schepper J PGM1 deficiency diagnosed during an endocrine work-up of low IGF-1 mediated growth 
failure. Acta Clin Belg. 2016 Dec;71(6):435-437. Epub 2016 May 24. 
11   Schrapers E, Tegtmeyer LC, Simic-Schleicher G, Debus V, Reunert J, Balbach S, Klingel K, Du Chesne I, 
Seelhöfer A, Fobker M, Marquardt T, Rust S.News on Clinical Details and Treatment in PGM1-CDG. JIMD 
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Presentation (statement #1: grade of recommendation C) 
PGM1-CDG can present with facial dysmorphic features, including 
micrognathia or retrognathia, bifid uvula, cleft hard palate, or full Pierre-
Robin sequence. The combined frequency of these findings is 85 %.  
Diagnosis and follow-up: (Statement #3: grade of recommendation D) 
Assessment by a clinical geneticist (evaluating for dysmorphic features) 
should be done at the time of the diagnosis. If bifid uvula or cleft hard 
palate is found, evaluation by a craniofacial specialist is warranted. If 
Pierre-Robin sequence is present, evaluation by an otolaryngologist is 
warranted, as a tracheostomy may be required to ensure airway patency. 
Ideally, evaluation should take place at a multidisciplinary craniofacial 
clinic, with access to specialists in otolaryngology, oral and maxillofacial 
surgery, plastic surgery, speech-language pathology, and dentistry. 
Treatment: (Statement# 4: grade of recommendation D) 
There is no disorder-specific management for congenital malformations in 
PGM1-CDG patients. Standard care for cleft palate and Pierre-Robin 
sequence should be pursued, such as surgical repair, feeding intervention, 




NEUROLOGICAL INVOLVEMENT  
Neurological phenotype is not a frequent presentation of PGM1-CDG. 
Normal neurodevelopment was stated in 17 PGM1-CDG patients. Motor 
delay was described in four patients (Ondruskova 201414, Nolting 2017, 
Ding 201815, Radenkovic 201916). Cognitive impairments were noted in 14 
patients, intellectual disability in 8, learning disabilities in 11 and speech 
delay in 2 (Ondruskova 2014, Tegtemeyer 201417, Wong 2016, Nolting 2017, 
Ding 2018). IQ was measured only in one patient and showed a global IQ of 
78 at 6 years and 66 at 10 years indicating cognitive regression (Ondruskova 
2014). In three patients, learning difficulties were stated as probably 
secondary to recurrent hypoglycemic episodes (Loewenthal 201518). 
Epileptic seizures have been reported in three patients with developmental 
delay, and abnormal EEG was detected in one patient (Wong 2016, Ding 
2018, Radenkovic 2019). No perinatal injuries or other plausible causes 
were reported. Brain MRI was normal in five patients and a thin pituitary 
was reported in one patient (Ding 2018). Other scarce neurological 
phenotypes included  left hemiplegia due to carotid thrombosis in one 
patient (Zeevaert 2016), and sensorineural deafness in another patient 
 
14 Ondruskova N, Honzik T, Vondrackova A, Tesarova M, Zeman J, Hansikova H. Glycogen storage 
disease-like phenotype with central nervous system involvement in a PGM1-CDG patient. Neuro 
Endocrinol Lett. 2014;35(2):137-41. 
15 Ding Y, Li N, Chang G, Li J, Yao R, Shen Y, Wang J, Huang X, Wang X.Clinical and molecular genetic 
characterization of two patients with mutations in the phosphoglucomutase 1 (PGM1) gene.J Pediatr 
Endocrinol Metab. 2018 Jul 26;31(7):781-788. doi: 10.1515/jpem-2017-0551 
16 Radenkovic S, Bird MJ, Emmerzaal TL, Wong SY, Felgueira C, Stiers KM, Sabbagh L, Himmelreich N, 
Poschet G, Windmolders P, Verheijen J, Witters P, Altassan R, Honzik T, Eminoglu TF, James PM, 
Edmondson AC, Hertecant J, Kozicz T, Thiel C, Vermeersch P, Cassiman D, Beamer L, Morava E, 
Ghesquière B. The Metabolic Map into the Pathomechanism and Treatment of PGM1-CDG. Am J Hum 
Genet. 2019 May 2;104(5):835-846. 
17 Tegtmeyer LC, Rust S, van Scherpenzeel M, Ng BG, Losfeld ME, Timal S, Raymond K, He P, Ichikawa M, 
Veltman J, Huijben K, Shin YS, Sharma V, Adamowicz M, Lammens M, Reunert J, Witten A, Schrapers E, 
Matthijs G, Jaeken J, Rymen D, Stojkovic T, Laforêt P, Petit F, Aumaître O, Czarnowska E, Piraud M, 
Podskarbi T, Stanley CA, Matalon R, Burda P, Seyyedi S, Debus V, Socha P, Sykut-Cegielska J, van 
Spronsen F, de Meirleir L, Vajro P, DeClue T, Ficicioglu C, Wada Y, Wevers RA, Vanderschaeghe D, 
Callewaert N, Fingerhut R, van Schaftingen E, Freeze HH, Morava E, Lefeber DJ, Marquardt T. Multiple 
phenotypes in phosphoglucomutase 1 deficiency.N Engl J Med. 2014 Feb 6;370(6):533-42. 
doi:10.1056/NEJMoa1206605. 
18 Loewenthal N, Haim A, Parvari R, Hershkovitz E. Phosphoglucomutase-1 deficiency: Intrafamilial 
clinical variability and common secondary adrenal insufficiency. Am J Med Genet A. 2015 Dec;167A 





(Nolting 2017). It is difficult to assess the impact of D-galactose 
supplementation in preventing CNS involvement in patients with PGM1-
CDG. 
Presentation (statement #1: grade of recommendation C) 
Cognition, motor development, speech, and hearing can be affected in 
multisystem PGM1-CDG.  Seizures can be primary or secondary to 
hypoglycemia .   
Diagnosis and follow-up (Statement# 2: grade of recommendation D) 
Neurological assessment should be done at the time of the diagnosis. EEG 
and brain MRI  should be considered if clinically indicated.  
Follow-up investigations should include early stimulation programs for the 
infants and toddlers, and psychometric tests and adaptations of 
educational programs when needed.  
Treatment (Statement# 3: grade of recommendation D) 
No specific treatment is available for the psychomotor delay and/or 
learning disabilities in PGM1-CDG besides early physical and speech 
therapy. Although the relationship between hypoglycemia and CNS 
involvement is not clear, diet or treatments to prevent CNS damage 





Ophthalmologic involvement is only reported with the multisystem  
PGM1-CDG. It has been reported in 6  patients. The most commonly 
reported ophthalmologic abnormalities were unspecified abnormal eye 
movements (n=2) (Wong 2016, Radenkovic 201819) and strabismus (n=2) 
(Wong 2016).  Less common findings were reading problems (n=1) 
(Ondruskova 2014), nasolacrimal duct obstruction and epiphoria (n=1) 
(Küçükçongar 2015). These results may be underestimated due to scarce 
data available with respect to ophthalmologic examination, management, 
and outcome.  
Presentation (statement #1; grade of recommendation C) 
PGM1-CDG can present with the following eye abnormalities; strabismus, 
abnormal eye movements, reading problems, nasolacrimal duct 
obstruction and/ or epiphoria. 
Diagnosis and follow-up (statement #2; grade of recommendation C) 
Ophthalmologic assessment is recommended standard of care of PGM1-
CDG.  
Management (statement #3; grade of recommendation C) 
Ophthalmologic abnormalities appear to be rare and should be treated 
individually, including surgery, if necessary. Standard supportive 





19 Radenkovic S, Witters P, Morava E. Central nervous involvement is common in PGM1-CDG.Mol Genet 




ENDOCRINE INVOLVEMENT  
Endocrine and growth problems are common  in PGM1-CDG, reported  in 
39 patients. Hypoglycemia was the main presentation, reported in 38 
patients and mostly due to hyperinsulinism in young patients and 
responding to diazoxide (Wong 2017, Ding 2018, Radenkovic 2018, 
Zeevaert, 2016). Ketotic hypoglycemic episodes secondary to starvation 
and/or febrile events have also been reported (Loewenthal 2015, 
Radenkovic 2018) which suggests the complexity of the hypoglycemia 
origins at different ages (Morava 201420). Hypoglycemic episodes can 
spontaneously resolve later in life (Loewenthal 2015). Oral administration 
of uncooked corn starch before bedtime was successful to prevent the 
hypoglycemia in one patient (Yokoi 201921), while the administration of 
hydrocortisone (12 mg/m2/day) reduced hypoglycemic events in another 
patient (Loewenthal 2015). Hypogonadotropic hypogonadism was 
reported in 3 patients (Tegtemeyer 2014, Zeevaert 2016); two of them 
presented with delayed puberty and decreased serum follicle-stimulating 
hormone (FSH). In both patients, D-galactose supplementation (0.5 to 1.0 
g/kg/day) resolved both features (Tegtemeyer 2014). Adrenal function 
deterioration was reported in 3 patients (Loewenthal 2015). High levels of 
serum thyroid-stimulating hormone (TSH) were reported in 3 patients and 
decreased levels of thyroxin-binding globulin (TBG) in 6 (Ondruskova 2014, 
Küçükçongar 2015, Wong 2017). Moreover, 7 patients presented with 
hypocortisolism and 5 of them had increased adrenocorticotropic 
hormone levels (Küçükçongar 2015, Lowenthal 2015, Zeevaert 2016, Ding 
2018). Twelve patients presented with decreased levels of growth 
hormone or IGF1 (Pérez 2012, Küçükçongar 2015, Loewenthal 2015, 
Schrapers 2016, Zeevaert 2016, Nolting 2017, Ding 2018, Ferlund et al 
2019) and nine patients showed decreased serum insulin-like growth 
factor-binding protein 3 (IGFBP-3) (Wong 2017, Ferlund et al 2019). Growth 
hormone therapy has been described in only 3 patients (Zeevaert 2017, 
 
20 Morava E.Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a 
novel treatable CDG.Mol Genet Metab. 2014 Aug;112(4):275-9. doi: 10.1016/j.ymgme.2014.06.002. 
Epub 2014 Jun 21. Review 
21 Yokoi K, Nakajima Y, Ohye T, Inagaki H, Wada Y, Fukuda T, Sugie H, Yuasa I, Ito T, Kurahashi H. 
Disruption of the Responsible Gene in a Phosphoglucomutase 1 Deficiency Patient by Homozygous 
Chromosomal Inversion.JIMD Rep. 2019;43:85-90. doi: 10.1007/8904_2018_108. Epub 2018 May 12. 
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Nolting 2017, Medrano 201922). Furthermore, Nolting (2017) reported a 
patient whose growth rate did not improve upon treatment with D-
galactose alone or in combination with uridine. 
 
Presentations (statement #1: grade of recommendation C) 
PGM1-CDG frequently presents with endocrine and growth problems, 
particularly, hyperinsulinemic hypoglycemia, hypogonadotropic 
hypogonadism, hypocortisolism, and delayed puberty. 
 
Diagnosis and follow-up: (Statement# 2: grade of recommendation D) 
The growth of PMG1-CDG patients as well as the serum levels of IGF-1, 
IGFBP3, TGB, TSH, free T4, ACTH, cortisol, and glucose should be assessed 
at the initial screening and regularly monitored.  
In addition, serum cortisol and ACTH should be assessed at the time of 
diagnosis and monitored as clinically indicated.  
 
Treatment: (Statement# 3: grade of recommendation D) 
There is no disorder-specific management for endocrine dysfunction in 
PGM1-CDG patients, although D-galactose supplementation can be used 
for its management.  
Hypoglycemia can be managed with the oral administration of uncooked 
corn starch before bedtime, in addition to frequent feedings and the use of 
complex carbohydrates.  
Oral diazoxide therapy should be considered for hyperinsulinemic 
hypoglycemia.  
Therapy with L-thyroxin is indicated for clinical hypothyroidism treatment.  
Cortisol supplements are recommended to treat hypocortisolism.  
 
22Medrano C, Vega A, Navarrete R, Ecay MJ, Calvo R, Pascual SI, Ruiz-Pons M, Toledo L, García-Jiménez 
I, Arroyo I, Campo A, Couce ML, Domingo-Jiménez MR, García-Silva MT, González-Gutiérrez-Solana L, 
Hierro L, Martín-Hernández E, Martínez-Pardo M, Roldán S, Tomás M, Cabrera JC, Mártinez-Bugallo F, 
Martín-Viota L, Vitoria-Miñana I, Lefeber DJ, Girós ML, Serrano Gimare M, Ugarte M, Pérez B, Pérez-
Cerdá C. Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders 




Growth impairment can be managed with growth hormone therapy, 




Twenty-four PGM1-CDG patients had cardiac manifestations as part of the 
multisystem involvement. . 
The main cardiac abnormality was cardiomyopathy (CM) with dilated 
cardiomyopathy as the most common type (n=12) (Tegtmeyer 2014, Timal 
2014, Loewenthal 2015, Zeevaert 2016, Wong et al 2016, Voermans 
201723, Nolting 2017, Fernlund 201924). CM resulted in cardiac arrest in 8 
patients, and heart failure in 4 patients. There is unpublished data about 
one patient who initially had restrictive cardiomyopathy, which evolved 
into combined dilated restrictive cardiomyopathy with predominant 
restrictive findings (personal communication). Electrocardiogram (ECG) 
abnormalities were stated in five patients including long QT interval, ST 
wave elevation, T wave inversion, sinus tachycardia, and minor incomplete 
intraventricular conduction disturbance. Other echocardiogram 
abnormalities include mild left ventricular enlargement (n=3), septal 
defects (n=2) and valvular heart defects (n=2). Cardiac manifestation in 
PGM1-CDG might be underreported due to the absence of screening for 
cardiac involvement before the first presentation of clinical features. The 
documented age of onset for cardiac findings was variable: within the first 
5 years (n=5), between 5 to 10 years (n=2) and after 10 years (n=6). The 
oldest age of onset was 49 years. There was limited information on the 
evolution of the cardiac manifestations with time but one patient was 
reported to have a normal cardiac function at 19 months of age but 
developed cardiomyopathy on follow-up. Six PGM1-CDG patients died 
from cardiac causes (Tegtmeyer 2014, Timal 2014, Loewenthal 2015, 
Zeevaert 2016). Sudden cardiac death in 12 and 13-year-old siblings 
diagnosed with PGM1-CDG was recently reported (Fernlund 2019). 
 
23 Voermans NC, Preisler N, Madsen KL, Janssen MC, Kusters B, Abu Bakar N, Conte F, Lamberti VM, 
Nusman F, van Engelen BG, van Scherpenzeel M, Vissing J, Lefeber DJ. PGM1 deficiency: Substrate use 
during exercise and effect of treatment with galactose. Neuromuscul Disord. 2017 Apr;27(4):370-376. 
doi: 10.1016/j.nmd.2017.01.014. Epub 2017 Jan 19. 
24 Fernlund E, Andersson O, Ellegård R, Årstrand HK, Green H, Olsson H, Gunnarsson C. 
The congenital disorder of glycosylation in PGM1 (PGM1-CDG) can cause severe cardiomyopathy 
andunexpected sudden cardiac death in childhood.Forensic Sci Int Genet. 2019 Nov; 43:102111. doi: 
10.1016/j.fsigen.2019.06.012. Epub 2019 Jun 17. 
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Presentation (Statement #1: grade of recommendation C) 
Cardiac involvement is mostly part of multisystem PGM1-CDG with 
variable age of presentation and onset. The most common cardiac feature 
is cardiomyopathy, specifically dilated cardiomyopathy. Conduction and 
structural heart abnormalities are less common. 
Diagnosis andfFollow-up (statement #2: grade of recommendation D) 
Cardiac assessment and baseline investigations should be done at the time 
of diagnosis and include creatine kinase MM (CK-MM), chest X-ray, 
echocardiogram and electrocardiogram (ECG). Further cardiac evaluation 
i.e. Holter monitor and exercise testing, should be done if clinically 
indicated.   
Annual cardiac screening is recommended, especially in childhood and 
adolescence.  Continued cardiology screening in affected adults should be 
considered.  
Treatment (statement #3: grade of recommendation D) 
There is no specific treatment for cardiac involvement in PGM1-CDG. 






Overt respiratory symptoms are rare manifestations of PGM1-CDG, 
reported in 8 patients due to congenital facial malformations,  underlying 
heart disease, or exercise intolerance (in the muscular form) (Timal 2012, 
Tegtmeyer 2014, Lowenthal 2015, Schrapers 2016, Voermans 2017, Tian 
201925).  
Upper airway obstruction (requiring a tracheostomy and placement of a 
tracheal tube) occurred in the neonatal period in one patient with Pierre 
Robin sequence (Lowenthal 2015). Two adult PGM1-CDG patients 
experienced breathing difficulties during physical exercise. In one patient, 
physical training led to considerable improvement, whereas galactose 
administration was reported to ameliorate the clinical status of the other 
patient (Schrapers 2016, Voermans 2017). Both patients showed mild to 
moderate cardiac involvement. 
Surgical correction of congenital facial malformations could lead to severe 
bleeding episodes and needed repeated surgery in several patients (Wong, 
2017).  I would like to add how many patients had tracheostomy and how 
long. I know of two patients, one is already de-trached (Dr.Morava’s 
comment) 
 
Presentations (statement #1: grade of recommendation C) 
PGM1-CDG seldom presents with overt respiratory symptoms. Breathing 
difficulties tend to occur when there are underlying congenital 
malformations (e.g. Pierre Robin sequence), severe cardiac dysfunction, 
especially and during intense physical exercise. Hence, respiratory 
involvement seems to be secondary to other clinical features.  
 
Diagnosis and follow-up: (Statement# 2: grade of recommendation D) 
The following investigations should be done at the time of the diagnosis: 
pulse oximetry, and more extensive exams upon clinical suspicion. In the 
 
25 Tian WT, Luan XH, Zhou HY, Zhang C, Huang XJ, Liu XL, Chen SD, Tang HD, Cao L. Congenital disorder 
of glycosylation type 1T with a novel truncated homozygous mutation in PGM1 gene and literature 





presence of congenital facial malformation, one should be wary of 
breathing difficulties. Surgical procedures such as tracheostomy and 
permanent correction of the malformations may be necessary.  
 
Treatment: (Statement# 3: grade of recommendation D) 
There is no specific treatment for respiratory symptoms in PGM1-CDG. 
Treatment of these manifestations is based on current clinical practice and 





GASTROINTESTINAL INVOLVEMENT  
 
Hard and/or soft cleft palate (with or without bifid uvula) and/or without 
Robin-Pierre sequence, were the most frequently presented congenital 
anomalies of the gastrointestinal (GI) tract, (refer to congenital 
malformation section). Feeding difficulties were reported in only 5 patients; 
one patient with dysphagia did not have cleft palate (Voermans 2016). One 
patient had an imperforate anus (Zeevaert 2016). One obese patient had 
cholecystolithiasis (Ondruskova 2014).  
Presentation (statement #1: grade of recommendation D) 
Gastrointestinal symptoms are not characteristic of PGM1-CDG patients 
while bifid uvula/cleft palate are frequent in the multisystem form.  
Diagnosis and follow-up (statement #2: grade of recommendation D) 
The diagnosis of cleft palate and Robin-Pierre sequence is clinical. An 
ultrasound scan of the abdomen is advised to exclude other possible 
congenital anomalies of the GI tract. 
Referrals to an oral and maxillofacial surgeon, nutritionist and speech 
therapist are recommended for the patients with cleft palate.  
Treatment (statement #3: grade of recommendation D) 
Treatment of the cleft palate should be guided by the oral and maxillofacial 
surgeons based on current practice and expertise. Patients with cleft palate 







Liver involvement has not been described in patients with the muscular 
form (Stojkovic 2009, Voermans 2017). On the other hand, all patients with 
the multisystem form presented with intermittent or chronically elevated 
serum transaminases (Pérez 2012, Timal 2012, Preisler 201326, Ondruskova 
2014, Tegtmeyer 2014, Küçükçongar 2015, Loewenthal 2015, Schrapers 
2016, Wong 2016, Zeevaert 2016, Nolting 2017, Preisler 2017, Wong 2017, 
Ding 2018, Yokoi 2018, Medrano 2019, Tian 2019, Radenkovic 2019). A 
positive effect of D-galactose treatment was observed, with an 
improvement of serum aspartate aminotransferase (AST) values and a 
normalization of alanine aminotransferase (ALT) values (Wong 2017, 
Radenkovic 2019). Hepatomegaly was only described in 2 patients but could 
be underreported (Ondruskova 2014, Küçükçongar 2015). Liver biopsy,  
performed in 5 patients, showed steatosis, cholestasis and/or slight fibrosis 
(Tegtmeyer 2014). Cirrhosis has not (yet) been reported. Glycogen 
accumulation, defined by increased PAS-positive staining, was observed in 
two out of five liver biopsies (Tegtmeyer 2014). There is insufficient data 
about the evolution of liver involvement in PGM1-CDG. Episodes of acute 
hepatic failure were described in 5 patients, however, without details 
concerning the circumstances or the extent of presentation (Wong 2016). 
The occurrence of acute liver failure did not correlate with the overall 
severity of the phenotype (Wong 2016). 
Presentation (statement #1: grade of recommendation C) 
Elevated serum transaminases are the most common biochemical finding 
of liver involvement in PGM1-CDG. In addition, steatosis, cholestasis, 
fibrosis, and episodes of acute hepatic failure may occur.  
Diagnosis and follow-up (statement #1: grade of recommendation D) 
 
 
26 Preisler N, Laforêt P, Echaniz-Laguna A, Ørngreen MC, Lonsdorfer-Wolf E, Doutreleau S, Geny B, 
Stojkovic T, Piraud M, Petit FM, Vissing J. Fat and carbohydrate metabolism during exercise in 
phosphoglucomutase type 1 deficiency. J Clin Endocrinol Metab. 2013 Jul;98(7):E1235-40. doi: 




Transaminases are the best markers to follow the disease progression and 
to use as treatment and compliance indicators. CDG screening tests should 
be considered in the instance of unexplained liver disease. 
Liver tests and biochemical markers of the liver's synthetic capacity should 
be monitored yearly.  Liver ultrasound should be performed at the time of 
diagnosis. Non-invasive elastography can be used to monitor the 
development of liver fibrosis. 
Treatment (statement #1: grade of recommendation D) 
D-Galactose treatment positively influences the transaminase levels in 




HEMATOLOGICAL/VASCULAR INVOLVEMENT  
Twenty-nine reported PGM1-CDG patients presented 
hematological/vascular anomalies. The coagulation anomalies included 
both procoagulant and anticoagulant factors. The most common 
abnormality was antithrombin III deficiency, present in 14 patients, whilst 
prolonged aPTT and elevated PT were found in 5 and two patients, 
respectively. Low factor XI was reported in 6 patients and low factor VII, IX, 
X, and XIII in two patients. Additionally, reduced levels of protein S and C 
were described in three patients.  
Isolated or recurrent thrombotic events were reported in 5 % of the 
patients. A cerebrovascular accident was the cause of death in an 8-year-
old patient who had left carotid artery thrombosis after an episode of 
transient hemiplegia at the age of 4 (Timal 2012, Zeevart 2016). In another 
patient, recurrent thrombosis developed after resuscitation from a cardiac 
arrest (Tegtmeyer 2014).  
Specific treatment for coagulation issues in PGM1-CDG patients was not 
reported. However, supplementation with D-galactose was found to 
improve antithrombin III levels in 5 patients (Wong 2017, Radenkovic 2019). 
 
Presentations (statement #1: grade of recommendation C) 
The main coagulation abnormality observed in PGM1-CDG is antithrombin 
III deficiency. PGM1-CDG can also be associated with factor VII, IX, X, XIand 
XIII deficiency, reduced protein C and S as well as increased PT and 
prolonged aPTT. Since procoagulant and anticoagulant factors can be 
affected, patients are susceptible to thrombotic and hemorrhagic events. 
 
Diagnosis and follow-up: (Statement #3: grade of recommendation D) 
At diagnosis, a complete blood count and hemostasis study should be 
performed, including PT and aPTT, antithrombin III, factors VII, IX, X and XIII, 
as well as protein C and S. Coagulation assessment should be done at least 
yearly. 
 
Treatment: (Statement #4: grade of recommendation D) 
There is no standard disease-specific treatment for coagulation anomalies 
in PGM1-CDG. Management procedures should be done according to 
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standard protocols considering the clinical status and history of the patient. 





Muscular involvement is a predominant feature of PGM1-CDG and can be 
similar to that of muscle glycogenosis with exercise intolerance, fatigability, 
muscle weakness and attacks of rhabdomyolysis (Stojkovic 2009). Muscular 
manifestation can be the only symptom of the disease. The primary 
muscular form can be related to specific PGM1 mutations (Wong 2016, 
March 1993). The degree of muscular involvement can be an important 
predictor of disease severity with more significant myopathy reported in 
severe phenotypes (Beamer 201527, Wong 2016, Radenkovic 2019). We 
reviewed data on 52 out of the 57 patients where the muscular symptoms 
were described in details. Any patients with only muscle symptoms? 
 
Exercise intolerance was reported in 20 patients (Sugie 1988, Gehrmann 
200328, Stojkovic 2009, Timal 2012, Tegtmeyer 2014, Ondruskova 2014, 
Voermans 2015, Wong 2016, Zeevaert 2016, Wong 2017, Radenkovic 
2019). A second wind phenomenon, patient's better tolerance for aerobic 
exercise such as walking and cycling after approximately 10 minutes of rest, 
was explicitly reported as absent in the patients reported by Stojkovic 2009, 
Preisler 2013 and Tegtmeyer, 2014, and present in the patient reported by 
Wong 2016. Cramps provoked by exercise were reported in one patient 
(Stojkovic 2009). 
 
Muscle weakness was reported in 18 patients, with very limited information 
on the pattern of muscle weakness. Only three patients were reported to 
have more weakness in the pelvic girdle and/or legs than in the upper 
extremities (Stojkovic 2009, Notting 2017, Tian 2019,). In one report, 
muscle weakness was proximal (Voermans 2017). 
 
27 Beamer LJ. Mutations in hereditary phosphoglucomutase 1 deficiency map to key regions of enzyme 
structure and function.J Inherit Metab Dis. 2015 Mar;38(2):243-56. doi: 10.1007/s10545-014-9757-9. 
Epub 2014 Aug 29. Review. 
28 
 Gehrmann J, Sohlbach K, Linnebank M, Böhles HJ, Buderus S, Kehl HG, Vogt J, Harms E, Marquardt T. 
Cardiol Young.Cardiomyopathy in congenital disorders of glycosylation. 2003 Aug;13(4):345-51. Review. 
25 
 
Hypotonia was  mentioned in only three patients (Sugie 1988, Ondruskova 
2014, Zeevaert 2016). Episodes of generalized hypotonia and hyporeflexia 
during episodes of metabolic decompensation were described in one 
patient (Sugie 1988).  
Myopathic gait and muscle wasting was described in only 2 patients who 
had predominant muscle symptomatology (Thompson 1963, Tian 2019). 
Abnormal toe gait from the age of 2.5 years was the major complaint of the 
first patient who also had muscular wasting but no exercise intolerance nor 
muscular pain (Thompson 1963). The second one presented with life-long 
muscle weakness, fatigability, and slow myopathic gait; muscle wasting was 
not mentioned (Tian 2019).  
Attacks of rhabdomyolysis were studied in 43 patients and occurred in 25 
% of patients (11/43). Patients suffered most often from moderate attacks 
with levels of creatine kinase (CK) from 10 000 to 50 000 IU/l(Tegtmeyer 
2014, Wong 2017). Severe rhabdomyolysis with renal failure was not 
described in any patient. The age of rhabdomyolysis was seldom 
mentioned; it occurred from infancy to adulthood. In one patient the first 
and only attack happened at 52 years (Voermans 2017). 
Chronic CK elevation was present in 65 % of patients (13/20) and in almost 
half of them (6/13) it was without any history of rhabdomyolysis. The 
maximum CK levels in those patients were 1.5 – 13 fold the upper normal 
limit (i.e. 300 - 2600 IU/l). Serum myoglobin was reported only in 4 patients 
(Marquardt 2014, Ondruskova 2014, Wong 2016, Wong 2017, Tian 2019) 
with normal levels. Other laboratory markers of muscle damage were not 
mentioned. 
Muscular involvement is part of the Tulane PGM1-CDG Rating Scale (TPCRS) 
(Wong 2016). The exact muscular subscore was mentioned in only 12 out 
of 52 patients, but it can be partially derived from the information in the 
articles in 46/52 patients. Moderate degree of myopathy (i.e. 2 TPCRS 
points) with generalized weakness, rhabdomyolysis, and/or exercise-
related pain was stated in 11 patients. Mild involvement with localized 
muscle weakness, and/or exercise intolerance (i.e. 1 TPCRS point) was 
present in 14 patients. Normal muscle tone was reported in 21 patients. 
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None of the patients was wheelchair-dependent or had respiratory 
compromise due to the myopathy. 
Clinical neurophysiological studies (electromyography (EMG), nerve 
conduction studies (NCS) were reported only in five patients. The EMG in 
two patients showed a myopathic pattern (Tian 2019, Stojkovic 2009). In 
another patient, EMG showed the myopathic pattern only during voluntary 
contraction consisting of polyphasic low-voltage potentials of short 
duration (quadriceps, gastrocnemii) (Thompson 1968). Normal nerve 
conduction studies and EMG were stated in two patients (Wong 2016, 
Zeevaert 2016). 
Muscle biopsy was performed in 12 patients; 10 biopsies were abnormal, 
showing myopathic changes (increase of internal nuclei or fiber size 
variation) and/or accumulation of fat or glycogen (Thompson 1963, Sugie 
1988, Stojkovic 2009, Timal 2012, Tegtmeyer 2014, Morava 2014, Tian 
2019) The fat accumulation, indicative for glycogen storage disease, was 
reported in 6 of these ten patients. In two patients, the biopsy was normal 
(Pérez 2013.Wong 2016) 
Twenty patients were treated with oral D-galactose in variable doses (0.5 – 
2.5 g/kg/day). The duration varied between 4.5 and 16.5 months. Six 
patients reported a positive effect on exercise intolerance and fatigability, 
and in one the effect was not clear. The number of rhabdomyolysis episodes 
did not decrease in any of the questioned 14 patients. CK elevation 
decreased after initiation of D-galactose (Wong 2016, Radenkovic 2019). 
Presentation (Statement #1: grade of recommendation C) 
Muscular involvement is one of the predominant features of PGM1-CDG. 
The main skeletal muscle manifestations are exercise intolerance, 
fatigability, muscle weakness and attack(s) of rhabdomyolysis. The disease 
can progress to significant generalized myopathy in about half of the 
patients with skeletal muscle involvement.  
Diagnosis and follow-up (Statement# 3: grade of recommendation D) 
Initial and annual neurological evaluation is recommended. According to 
the disease progression, neurophysiological studies should be performed. 
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Muscle biopsy investigation is not required to diagnose PGM1-CDG and the 
invasiveness of this procedure limits its indication to research purposes. 
Because of the risk of marked myoglobinuria, serum creatine kinase and 
myoglobin level determination are warranted during any acute intercurrent 
infections and each time when the patient complains about sudden 
episodes of myoglobinuria, muscle pain, swelling and /or weakness. In case 
of rhabdomyolysis, treatment should be focused at prevention of kidney 
failure and metabolic abnormalities.       
Treatment: (Statement# 4: grade of recommendation D) 
Dietary D-galactose supplementation should be considered in all patients 
since a positive effect on exercise intolerance, fatigability and reduction of 





MALIGNANT HYPERTHERMIA SUSCEPTIBILITY  
There is limited information in the literature about surgeries and 
anesthetic agents used in PGM1-CDG patients.  The most common 
reported surgery is cleft palate repair.  Malignant hyperthermia was 
reported in only 2 patients of 22 operated PGM1-CDG patients (one of 
whom had a history of exercise intolerance, and rhabdomyolysis was 
reported in both patients (Tegtmeyer 2014, Marquardt 2014). Detailed 
anesthetic information, including anesthetic agents used for surgery, was 
only reported in one patient (Marquardt 2014). Halothane was the 
anesthetic agent used for cleft palate repair and it was associated with 
malignant hyperthermia.  The diagnosis was based on the clinical grading 
scale previously reported by Larach 199429.  Propofol and remifentanyl 
were reported to cause minor rise in CK in the same patient (Marquardt 
2014). Pseudocholinesterase activity, when measured, was reported to be 
low and this was associated with risk of prolonged recovery from 
anesthetic agents in children (Tegtmeyer 2014, Soliday 201030). 
Presentation (Statement #1: grade of recommendation D) 
Malignant hyperthermia was reported in PGM1-CDG in association with 
the use of Halothane 
Diagnosis and follow-up (statement #2: grade of recommendation D) 
Malignant hyperthermia may be a risk, particularly in PGM1 patients with 
skeletal myopathy and rhabdomyolysis. Pre-anesthetic evaluation is 
strongly recommended for PGM1 patients undergoing surgery. 
Pseudocholinesterase activity can be measured in patients with PGM1-
CDG.   
Treatment (Statement #2: grade of recommendations D)  
 
29 Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, 
Nelson TE, Ording H. A clinical grading scale to predict malignant hyperthermia susceptibility. 
Anesthesiology. 1994 Apr;80(4):771-9 
30 Soliday FK, Conley YP, Henker R.  Pseudocholinesterase deficiency: a comprehensive review of 
genetic, acquired, and drug influences.  AANA J. 2010 Aug;78(4):313-20 
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Caution should be exercised with the use of anesthetic agents, particularly 
depolarizing muscle relaxants and volatile anesthetic agents in patients 
with PGM1-CDG.   
 ADULT PRESENTATION  
There are 15 adult patients with PGM1-CDG described in the medical 
literature, including one patient who was described as a 13 year-old and 
subsequently as a 32 year adult (Pérez 2012, Medrano 2019). PGM1-CDG 
patients can live into adulthood but frequently present to medical care in 
infancy with classic presentations of PGM1-CDG, including congenital 
anomalies, hypoglycemia, hepatopathy, and cardiomyopathy. Some adult 
patients had mild presentations that delayed diagnosis, including 
recurrent exercise-induced myopathy with and without rhabdomyolysis, 
muscular fatigue, and short stature. Severe symptoms can persist into 
adulthood, including hypoglycemia, cardiomyopathy, and hepatopathy. 
Presentation (Statement #1: grade of recommendation D) 
Adult patients presenting with recurrent myopathy or rhabdomyolysis 
should be evaluated for PGM1-CDG. 
Diagnosis and Follow up (Statement# 3: grade of recommendation D) 
Adult PGM1-CDG patients should continue to have ongoing health 
screening at least annually. 
Treatment: (Statement# 4: grade of recommendation D) 





1) BIOCHEMICAL DIAGNOSIS 
1.1 Transferrin and N-glycan analysis 
The serum transferrin (Tf) analysis by isoelectric focusing (TIEF), capillary 
electrophoresis (CE), High-Performance Liquid Chromatography (HPLC), or 
by Liquid Chromatography coupled with Mass Spectrometry (LC/MS) has 
been used in diagnostic testing of different GDG. (supplementary table 3)  
All the above-mentioned methods are based on monitoring glycosylation 
changes in serum Tf. This protein is abundant in serum and has two N-
linked glycan attached to the Tf protein. The most abundant Tf species in 
healthy controls is Tf which bears two complete oligosaccharide chains 
(tetrasialotransferrin), which is represented by a major band on IEF gel. 
CDG-I presents with increased transferrin missing both or one 
oligosaccharide chain represented by two additional IEF bands 
(asialotransferrin, disialotransferrin) consistent with missing glycan chains 
(type 1 pattern), while CDG-II has transferrin with truncated 
oligosaccharide chains represented by more IEF bands (asialo, monosialo, 
disialo, trisialo, tetrasialotransferrin)(type 2 pattern).  
The majority of reported PGM1-CDG patients presented with a mixed 
TIEF-1/2 pattern, a phenomenon so far seen only in PGM1-CDG. This 
profile suggests that this disorder affects both ER (CDG-I) and Golgi 
apparatus (CDG-II)-associated glycosylation. This has partially been 
explained by the depletion of UDP-glucose and UDP-galactose in PGM1-
CDG patients. These sugar nucleotides are essential glycan building blocks 
involved in ER and GA glycosylation processes respectively (Radenkovic 
2019).  
The most commonly used method in the diagnosis of CDG is TIEF; it has 
been performed in more than 81 % of the reported PGM1-CDG patients 
(Perez 2012, Timal, 2012, Ondruskova 2014, Socha 2014, Tegtmeyer 2014, 
Kucukcongar 2015, Lowenthal 2015, Schrapers 2015, Zeevaert 2016, 




TIEF is a fast and easily applicable laboratory technique in clinical settings. 
However, it is not the ideal method, as the results are not always 
conclusive and often fluctuate, which is particularly common in the first 
months of life. Moreover, abnormal TIEF patterns sometimes resolve on 
growing older, regardless of the patient’s disease progression. In addition, 
the changes in TIEF are not limited to CDG and can be seen in other 
conditions, such as liver pathologies, endocrine anomalies and infections 
(Bean 199531, Bean 199832, Charlwood 199833, Helander 200134, Kaphalia 
201435). Therefore, additional methods assessing patient’s glycosylation 
status are highly recommended. 
More robust and useful methods including different Mass-Spectrometry 
MS techniques like LC/MS are generally recognized as being capable of 
identifying PGM1-CDG (Tegtmeyer 2014). They also offer the possibility to 
monitor the patients’ response to treatment  (Voermans 2015, Wong 
2017) 
The LC/MS pattern of PGM1-CDG is unique and characteristic for all 
confirmed patients.  It is a pathognomonic pattern of transferrin missing 
one entire glycan while the remaining glycans are truncated at the 
galactose level (Tegtmeyer 2014).   
Analysis of intact transferrin (Van Scherpenzeel 201536) and total plasma 
N-glycoproteins by HPLC-CHIP-QTOF LC-MS (Abu Bakar 201837) has also 
 
31 Bean P, Sutphin MS, Liu Y, Anton R, Reynolds TB, Shoenfeld Y, Peter JB. 
Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary 
cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies. Clin Chem. 1995 Jun;41(6 
Pt 1):858-61. 
32   Bean P, Husa A, Liegmann K, Sundrehagen E. Semi-automated carbohydrate-deficient transferrin in 
primary biliary cirrhosis: a pilot study. Alcohol Alcohol. 1998 Nov-Dec;33(6):657-60 
33 Charlwood J, Clayton P, Keir G, Mian N, Winchester B.Defective galactosylation of serum transferrin 
in galactosemia.Glycobiology. 1998 Apr;8(4):351-7 
34   Helander A, Eriksson G, Stibler H, Jeppsson JO. Interference of transferrin isoform types with 
carbohydrate-deficient transferrin quantification in the identification of alcohol abuse. Clin Chem. 
2001;47(7):1225-33 
35 Kaphalia BS. Biomarkers of acute and chronic pancreatitis. In: Biomarkers in Toxicology, edited by 
Gupta RC, editor. San Diego, CA: Elsevier/Academic, 2014, p. 279–289. doi:10.1016/B978-0-12-404630-
6.00016-6 
36 van Scherpenzeel M, Steenbergen G, Morava E, Wevers RA, Lefeber DJ. High-resolution mass 
spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the 
congenital disorders of glycosylation. Transl Res. 2015 Dec;166(6):639-649.e1. 
37 Abu Bakar N, Voermans NC, Marquardt T, Thiel C, Janssen MCH, Hansikova H, Crushell E, Sykut-
Cegielska J, Bowling F, MØrkrid L, Vissing J, Morava E, van Scherpenzeel M, Lefeber DJ. Intact transferrin 
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been reported and could additionally be used to screen for different CDG 
including PGM1-CDG. However, total plasma N-glycan profiling does not 
give insight into the absence of glycan forms, given the fact that it 
depends on relative protein abundance. To circumvent this problem, the 
authors have specifically defined 3 glycan indexes which can be extracted 
from transferrin QTOF spectra and can be used to recognize PGM1-CDG.  
Other used methods for N-glycan analysis in CDG include MALDI-TOF (Xia 
201338, Nolting 2017), ESI-MS (Lacey 200139) and ESI-QTOF (Chen 201940). 
Though MALDI-TOF is a more preferred method in CDG diagnostics due to 
its ease of use, robustness and the low amount of material necessary for 
the analysis, it isnot superior to other methods for this particular CDG.  
The analysis of other highly glycosylated proteins such as apoC-III is 
commonly used during CDG diagnosis as a complementary analysis to 
transferrin analysis (Wopereis 200341, Lefeber 201442, Ondruskova 
201543). Most PGM1-CDG patients have a normal apoC-III profile 
(Tegtmeyer 2014, Wong 2017, Abu Bakar 2018), with only a few 
exceptions (Ondruskova 2015). 
 
and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I 
deficiency. Transl Res. 2018 Sep; 199:62-76 
38Xia B, Zhang W, Li X, Jiang R, Harper T, Liu R, Cummings RD, He M. Serum N-glycan and O-glycan 
analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. Anal Biochem. 2013 
Nov 15;442(2):178-85    
39 Lacey JM, Bergen HR, Magera MJ, Naylor S, O'Brien JF. Rapid determination of transferrin isoforms by 
immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin Chem. 2001 
Mar;47(3):513-8. 
40   Chen J, Li X, Edmondson A, Meyers GD, Izumi K, Ackermann AM, Morava E, Ficicioglu C, Bennett MJ, 
He M. Increased Clinical Sensitivity and Specificity of Plasma Protein N-Glycan Profiling for Diagnosing 
Congenital Disorders of Glycosylation by Use of Flow Injection-Electrospray Ionization-Quadrupole Time-
of-Flight Mass Spectrometry. Clin Chem. 2019 May;65(5):653-663  
41 Wopereis S, Grünewald S, Morava E, Penzien JM, Briones P, García-Silva MT, Demacker PN, Huijben 
KM, Wevers RA.Apolipoprotein C-III isofocusing in the diagnosis of genetic defects in O-glycan 
biosynthesis. Clin Chem. 2003 Nov;49(11):1839-45 
    Lefeber DJ, Morava E, Jaeken J. How to find and diagnose a CDG due to defective N-glycosylation. J 
Inherit Metab Dis. 2011 Aug;34(4):849-52 
  Ondrušková N, Honzík T, Kytnarová J, Matoulek M, Zeman J, Hansíková H. Isoelectric Focusing of Serum 
Apolipoprotein C-III as a Sensitive Screening Method for the Detection of O-glycosylation Disturbances. 
Prague Med Rep. 2015;116(2):73-86 
42 Lefeber DJ, Morava E, Jaeken J. How to find and diagnose a CDG due to defective N-glycosylation. J 
Inherit Metab Dis. 2011 Aug;34(4):849-52  
43 Ondrušková N, Honzík T, Kytnarová J, Matoulek M, Zeman J, Hansíková H. Isoelectric Focusing of 
Serum Apolipoprotein C-III as a Sensitive Screening Method for the Detection of O-glycosylation 
Disturbances. Prague Med Rep. 2015;116(2):73-86 
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Statement #1 (grade of recommendation: B) 
PGM1-CDG patients present with a  mixed type 1 and type 2 TIEF pattern 
(a combination of asialo, monosialo, disialo, trisialo and 
tetrasialotransferrin). 
1.1.2 Therapy monitoring using Tf and N-glycan analysis  
LC/MS and MALDI-TOF based methods can be used for monitoring D-
galactose therapy that improves the restauration of incomplete N-glycans 
faster than that of unoccupied glycosylation sites. The latter is easily 
monitored by MALDI-TOF approach. For the practical and routine clinical 
laboratory use the HPLC-CHIP-QTOF LC/MS of total plasma N-glycans 
method can also be used to closely monitor the effect of D-galactose 
therapy outcome in PGM1-CDG patients using 3-glycan index (Abu Bakar 
2018).  
Statement #1 (grade of recommendation: B) 
LC-MS platforms are the recommended methodology for monitoring 
therapy effectiveness in PGM1-CDG patients. 
1.2 Enzymatic studies  
Most PGM1-CDG patients have severely diminished PGM1 enzymatic 
activity.. Fibroblasts and leukocytes (red blood cells should not be used as 
PGM1 is absent) are commonly used for enzymatic studies. PGM1 activity 
can also be measured in  muscle tissue but due to the most reliable assay, 
fibroblasts are usually preferred (Tegtmeyer et al, 2014). 
The enzymatic activity of PGM1 in reported patients ranges from 
undetectable to 20 % of controls (Stojkovic 2009, Perez 2012, Timal 2012, 
Preisler 2013, Beamer 2014, Lee 2014, Ondruskova 2014, Socha2014, 
Tegtmeyer 2014, Wong 2016Zeevaert 2016, Nolting 2017, Preisler 2017 
Voermans 2017, Wong 2017, Yokoi 2018, Radenkovic2019). Unusually, 
PGM1 activity doesn’t correlate with the severity of the patient’s 
phenotype and the differences in activities of other PGM isoforms have 
been proposed as one of the possible explanations (Tegtmeyer 2014, 
Wong 2016). It is important to note that, although enzymatic studies are 
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informative, they are not substantial for assessing the severity of the 
patient’s phenotype and predicting the outcome.  
Statement#1 (Grade of recommendation: D) 
PGM1 enzymatic assays are frequently used in PGM1-CDG as 
complementary analysis and most of the patients present with <20 % 
enzymatic activity. Patient fibroblasts or leukocytes can be used for 
enzymatic studies. However, the final diagnosis is based on molecular 
testing.  
1.3 Other biochemical analyses 
Galactose-related metabolites (blood galactose-1-P levels, urine galactitol 
levels)can be measured in order to screen for PGM1 deficiency 
(Tegtmeyer 2014) and to monitor the safety of D-galactose therapy (Wong 
2017). Interestingly, red blood cell galactose-1-P is paradoxically elevated 
in untreated PGM1-CDG patients  in a mild to moderate degree 
(Tegtmeyer 2014). Therefore, galactosemia screening based on galactose-
1-P levels in newborn screening (NBS) can show false positive results in 
PGM1- deficient patients. This marker could be used in early disease 
screening and potentially NBS. Patients who are started on galactose 
therapy should be monitored, as high levels of galactose-1-P could be 
toxic. The maximum daily D-galactose limit which is considered to be safe 
is 50 g (De Smet 200944) and increased galactitol excretion has only been 
reported in patients receiving more than 50 g/day (Wong 2017).   
In order to understand the pathomechanisms of the disease, an extended 
analysis of galactose metabolism  has been reported (Radenkovic 2019). 
This approach used a variety of (tracer) MS techniques such as GC-MS and 
LC-MS,  to elucidate the role of galactose in the treatment of PGM1-CDG. 
These labor-intensive and costly techniques are highly informative but not 
used in clinical practice. 
Statement#1 (Grade of recommendation: C) 
 
44 De Smet E, Rioux JP, Ammann H, Déziel C, Quérin S. FSGS permeability factor-associated nephrotic 
syndrome: remission after oral galactose therapy. Nephrol Dial Transplant. 2009 Sep;24(9):2938-40 
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Galactose-1-phosphate is mildly increased in untreated patients with 
PGM1-CDG. In order to monitor the safety of D-galactose therapy, 
galactose related metabolites (galactitol in urine) can be tested.  
1.4 Sensitivity of biochemical testing  
Though the majority of PGM1-CDG patients present with a mixed TIEF 
pattern, some patients can present with a type 1 or a type 2 pattern 
(Socha 2014, Perez 2012, Kucukcongar 2015, Zeevaert 2016, Nolting 
2017). Therefore, PGM1-CDG should not be excluded solely on the basis of 
the TIEF results. Complementary glycosylation analysis, enzymatic assays 
and genetic testing should be included.  
Statement #1 (Grade of recommendation: D) 
Though the majority of PGM1-CDG patients present with a mixed TIEF 
pattern, some patients present with a type 1 or a type 2 pattern in which 
case it is recommended to use other methods in order to make a correct 
diagnosis. 
1.5 Pre-analytical requirements for biochemical testing 
Detailed statements on transferrin analysis sensitivity and the pre-
analytical requirements for the biochemical testing are given in the 
PMM2-CDG guidelines (Altassan 201945). 
1.6 False positives 
Aberrant glycosylation patterns can also be detected in individuals 
affected by other genetic disorders with secondary glycosylation defects 
such as galactosemia (Charlwood 1998) or hereditary fructose intolerance 
(Adamowitz 200746).  Note that galactosemia shows also a combined TIEF 
type1/type 2 pattern! Moreover, various conditions affecting the liver 
(e.g. alcoholism, infections, immune disorders) can similarly affect 
 
45 Altassan R, Péanne R, Jaeken J, Barone R, Bidet M, Borgel D, Brasil S, Cassiman D, Cechova A, Coman 
D, et al. International clinical guidelines for the management of phosphomannomutase 2-congenital 
disorders of glycosylation: Diagnosis, treatment and follow up.J Inherit Metab Dis. 2019 Jan;42(1):5-28 
46 Adamowicz M, Płoski R, Rokicki D, Morava E, Gizewska M, Mierzewska H, Pollak A, Lefeber DJ, 
Wevers RA, Pronicka E. Transferrin hypoglycosylation in hereditary fructose intolerance: using the clues 
and avoiding the pitfalls. J Inherit Metab Dis. 2007 Jun;30(3):407. Epub 2007 Apr 2 
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glycosylation, leading to mainly Golgi-related glycan abnormalities (glycan 
truncation).  
Statement #1 (Grade of recommendation: C) 
The presence of other clinical conditions should also be excluded in case 
of abnormal TIEF results. 
2) MOLECULAR DIAGNOSIS 
2.1 Genetic testing 
PGM1-CDG can further be confirmed by standard genetic tests such as 
Sanger sequencing, whole-exome sequencing (WES) or homozygosity 
mapping. 
PGM1-CDG is located on  chromosome 1 and contains 11 exons. So far, 41 
different variants in PGM1 have been reported spanning across the whole 
PGM1 gene. The most common variant is c.112A>T (n=9) located in the 
first exon, followed by c.988G>C (n=5) and c.787G>T (n=4). The majority of 
variants are missense (24) or frameshift/nonsense variants (11), with only 
a few splicing (4) and gross rearrangement type of variants reported (1). 
The frequency of compound heterozygotes and homozygotes is 
approximately similar in PGM1-CDG while deletions (n=2) and inversions 
(n=1) are very rare. (Supplementary Table 4) 
Statement #1 (grade of recommendation: A) 
Genetic testing is the standard method  to confirm PGM1-CDG diagnosis.  
2.2 Genotype-phenotype correlations 
As mentioned earlier, PGM1-CDG phenotypes do not correlate with PGM1 
enzymatic activities. Furthermore, several PGM1 variants  do not correlate 
with phenotype severity,  clinical outcome or  response to D-galactose 
therapy.  
One possible explanation  is the existence of different PGM isoforms. For 
example, PGM2, which is the predominant PGM isoform in red blood cells, 
may be more active in some patients and therefore able to take over the 
role of PGM1 to some extent (Tegtmeyer 2014). However, PGM1 remains 
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the most important PGM isoform responsible for the interconversion of 
glucose-6-P into glucose-1-P and the discrepancy in the activities of 
different isoforms can provide only a partial explanation. Therefore, 
further studies are needed to understand the lack of the correlation 
between the genotype and phenotype in PGM1-CDG. 
Statement #1 (grade of recommendation: C) 
No genotype/phenotype correlation has been seen in PGM1-CDG. A 
partial explanation can come from the existence of different PGM 
isoforms, but more insight is needed in order to understand these 
discrepancies.  
3) Common laboratory findings 
Standard laboratory testing in PGM1-CDG usually reveals low or 
fluctuating glucose levels as well as elevated serum transaminases. 
Decreased coagulation factors including antithrombin-III, factor IX, factor 
XI, etc. and prolonged PT and aPTT are also common. In addition, the 
majority of PGM1-CDG patients, especially those with exercise 
intolerance, present with high creatine kinase (CK) levels. Other  
laboratory findings include altered plasma concentrations of cortisol, 
ACTH, GH, IGF1, IGFBP3, gonadotrophins (LH, FSH) and thyroid hormones 
(Stojkovic 2009, Perez 2012, Tegtmeyer 2014, Ondruskova 2014, 
Lowenthal 2015, Kucukcongar 2015, Voermans 2017, Preisler2017, Nolting 
2017, Wong 2017, Ding 2018, Yokoi 2018, Radenkovic 2019, Tian 2019, 
Medrano 2019, Tian 2019). Global protein hypoglycosylation is also a 
common finding in PGM1-CDG (Abu Bakar 2018).  
Spontaneous improvement of overall glycosylation, as has been seen in 
adult CDG patients,, especially in CDG-I (Witters 201947) has never been 
observed in PGM1-CDG. 
Monitoring mentioned laboratory findings is helpful during D-galactose 
therapy. Coagulation parameters and liver enzymes usually normalize 
 
47 Witters P, Honzik T, Bauchart E, Altassan R, Pascreau T, Bruneel A, Vuillaumier S, Seta N, Borgel D, 
Matthijs G, Jaeken J, Meersseman W, Cassiman D, Pascale de L, Morava E. Long-term follow-up in 
PMM2-CDG: are we ready to start treatment trials? Genet Med. 2019 May;21(5):1181-1188 
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during the first year of the treatment. Similarly, CK levels improve on long 
term D-galactose therapy while glucose levels tend to fluctuate without 
additional nutritional intervention, frequent complex carbohydrate 
treatment or diazoxide therapy (Wong 2017, Radenkovic 2019). In 
addition, the overall glycosylation of secretory glycoproteins improves on 
D-galactose therapy and is easily monitored as well (Abu Bakar 2018). The 
improvement of the patients’ laboratory findings correlates with their 
outcome and therefore it is highly informative for the therapy compliance 
as well (Wong 2017, Radenkovic 2019).  
Statement #1 (Grade of recommendation: B) 
Low blood sugar levels, elevated transaminases, and decreased 
antithrombin activity are the most consistently altered biochemical 
markers in patients with PGM1-CDG. Similarly, changes in other laboratory 
parameters such as aPTT, factor VIII, factor XI, CK, LH, FSH are frequent. 
Hence, their levels should be closely monitored, especially during therapy. 
Liver enzymes, thyroid hormones as well as coagulation factors normalize 
on long term D-galactose therapy and are easily monitored, while blood 
sugar levels might fluctuate regardless of D-galactose therapy.  
4) Prenatal testing, screening and genetic counseling 
Although the detection of PGM1 deficiency is possible from dried blood 
spots using a modified Beutler test (Tegtmeyer 2014), currently there is no 
newborn screening available for PGM1-CDG. Prenatal genetic testing can 
be done if the parents are known carriers of PGM1-CDG or if there is a 
family history of PGM1-CDG. TIEF of fetal plasma results are not 
conclusive and therefore not recommended (Matthijs 199848).  
Genetic counseling is an important part of PGM1-CDG diagnosis and 
should be offered to any parents with a child suspected or diagnosed with 
PGM1-CDG. 
Statement #1 (grade of recommendation B) 
 
48 Matthijs G, Schollen E, Cassiman J-J, Cormier-Daire V, Jaeken J, van Schaftingen E. Prenatal diagnosis 
in CDG1 families: beware of heterogeneity. Eur J Hum Genet. 1998;6(2):99-104. 
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Molecular analysis of PGM1  is the gold standard of the diagnosis  at any 
age in any individual with a suspected PGM1 deficiency.  However, after 
birth, additional biochemical studies might be needed in case of the 






D-Galactose therapy in PGM1-CDG is able to restart the glycosylation by 
replenishing nucleotide sugar pools UDP-glucose and UDP-galactose 
necessary for ER linked glycosylation and Golgi linked glycosylation, 
respectively (Radenkovic 201949). 
Regarding the clinical aspect, D-galactose supplement was trialed in more 
than 20 PGM1-CDG patients and has shown marked improvement of most  
symptoms including exercise intolerance, fatigability, hypogonadism, 
delayed puberty, rhabdomyolysis and the frequency of hypoglycemias 
(Tegtmeyer 2014, Schrapers 2015, Wong 2017, Nolting 2017, Radenkovic 
2019).  On the laboratory side, long-term follow-up of PGM1-CDG patients 
trialed on galactose showed an improvement in transaminase levels, 
normalization of antithrombin III and FSH levels and reduction in CK levels 
(Tegtmeyer 2014, Morava 2014, Schrapers 2016, Voermans 2017, Wong 
2017, Radenkovic 2019). In addition to D-galactose therapy, enrichment of 
the diet with complex carbohydrates is essential to maintain normal blood 
glucose levels  in all PGM1-CDG patients (Witters 201750).  
N-glycosylation changes were monitored by different methods in multiple 
patients (Tegtemeyer 2014, Schrapers 2016, Nolting 2017, Voermans 2017, 
Wong 2017, Abu Bakar 2018, Chen 2019) during galactose therapy and 
showed sustained improvement in all except one (Nolting 2017). 
The trialed galactose dose was ranging between 0.5 to 3 g/kg / day 
(maximum dose 50 g /day) and showed no adverse effects in most patients 
(Tegtmeyer 2014, Schrapers 2016, Voermans 2017, Nolting 2017, Wong 
2017, Radenkovic 2019). One patient did not tolerate higher doses of D-




49 Radenkovic S, Bird MJ, Emmerzaal TL, Wong SY, Felgueira C, Stiers KM, Sabbagh L, Himmelreich N, 
Poschet G, Windmolders P, Verheijen J, Witters P, Altassan R, Honzik T, Eminoglu TF, James PM, 
Edmondson AC, Hertecant J, Kozicz T, Thiel C, Vermeersch P, Cassiman D, Beamer L, Morava E, 
Ghesquière B.The Metabolic Map into the Pathomechanism and Treatment of PGM1-CDG. Am J Hum 
Genet. 2019 May 2;104(5):835-846. doi: 10.1016/j.ajhg.2019.03.003. Epub 2019 Apr 11. 
 
50 Witters P, Cassiman D, Morava E. Nutritional Therapies in Congenital Disorders of Glycosylation 
(CDG). Nutrients. 2017 Nov 7;9(11). pii: E1222. doi: 10.3390/nu9111222. Review. 
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It is important to note, however, that although D-galactose is able to 
alleviate multiple symptoms and improve patient outcome, it is not an ideal 
treatment. The patients have to consume high amounts of this sugar as well 
as other complex carbohydrates, and a consult with a dietician is 
recommended.  
 
Characteristic (Statement #1: grade of recommendation D) 
Oral D-galactose supplementation is a recommended treatment for 
PGM1-CDG patients presenting with hypoglycemia, rhabdomyolysis, 
coagulopathy, and or hepatopathy. 
Method of administration (Statement #2: grade of recommendation D) 
The recommended galactose dose starts at 0.5-3 g/kg/dose orally 4 to 5 
times daily. The maximum recommended dose is 50 g/ day.  
Monitoring of treatment (Statement #3: grade of recommendation D) 
Monitoring of transaminases (ALT, AST), anticoagulation factors (ATIII) as 
well as CK levels is recommended especially at the start of treatment. In 
addition, N-glycosylation improvements should be monitored for 
treatment efficacy. Methods such as intact transferrin analysis, or more 
potent LC/MS methods can be used.  
Undesirable effects (Statement #4: grade of recommendation D) 
Higher doses of galactose treatment might not be tolerated in all patients 
and therefore should be carefully considered. Doses higher than 50 g/day 
should be avoided as galactose can result in the increase of galactose-1-P 




Table 1: the most commonly reported phenotypes in PGM1-CDG  
System*  Phenotype no. of patients 
malformations cleft palate  28 
 bifid uvula 25 
 Pierre-Robin sequence 15 
Neurologic developmental delay  11 
 cognitive impairment  14 
 intellectual disability  8 
 learning disabilities  11 
Endocrine hypoglycemia 38 
 hypocortisolism 7 
 high adrenocorticotropic hormone 5 
 low GH or IGF1 11 
 low IGFBP-3 8 
Cardiac  dilated cardiomyopathy 12 
 structural abnormalities  7 
 
abnormal ECG (long QT interval, ST elevation, T 
inversion, others) 5 
Hepatic  increased transaminases  42 
  steatosis  7 
 acute liver failure 5 
Hematologic coagulopathy 29 
Muscular  rhabdomyolysis  42 
 exercise intolerance  20 
 muscle weakness 18 
 chronic CK elevation 13 




Table 2: Clinical presentation in patients with PGM1 deficiency and suggested surveillance  
Phenotype Suggested surveillance frequency  






Complete physical examination at the time of diagnosis and referral to necessary services  
Neurological cognitive delay, 
seizure  
Complete physical examination at the time of diagnosis and yearly developmental assessment. EEG and 
brain MRI if clinically indicated   




obstruction and/ or 
epiphoria 
Eye exam at the time of diagnosis and monitoring if clinically indicated  





Assessment of growth at the time of diagnosis and on follow-up. Serum levels of IGF-1, IGFBP3, TGB and TSH 
at the time of diagnosis and regularly monitored.  






Electrophysiology (ECG) and echocardiography at the time of diagnosis and monitored if clinically indicated  
Muscle exercise intolerance, 
myopathy, 
rhabdomyolysis 
CK at the time of diagnosis, then if clinically indicated (during acute illnesses); neurophysiological study if 





acute hepatic failure 
Transaminases and hepatic function at time of diagnosis and monitored regularly  
Hematological anthithrombin III, 
factors XI, VII, IX, X 
and XI deficiencies 
low proteins C and S, 
increased PT and 
prolonged aPPT 
Coagulation profiles at the time of diagnosis and monitored regularly  
Metabolic  hypoketotic and 
ketotic hypoglycemia 
Glucose level at the time of diagnosis and during illnesses with urine ketones and insulin levels  
Other  malignant 
hyperthermia  
Caution is advised in regard of choice of anaesthetics  





Table 3: N- glycosylation analysis methods in PGM1-CDG  






Easily applicable, fast, cheap, PGM1-
CDG specific mixed CDG-I/II pattern, no 
enzymatic digestion 
Results are difficult to be quantified, 
not high-throughput, 
false positive in several metabolic and 
liver conditions, 
false negative at very young age and 






Rapid, easy to use, more accurate than 
TIEF, easy to implement, no enzymatic 
digestion, high-throughput, can be 
compared to the existing databases, 
protein specific glycosylation 
Lower sensitivity compared to LC/MS, 
lower accuracy and specificity,  






High-throughput, no enzymatic 
digestion, detailed glycan assessment, 
PGM1-CDG specific, robust, protein 
specific glycosylation, semiquantitative 
(internal standards) 
Detailed analysis and interpretation of 
data 
Time consuming, more expensive 
No information about the glycosylation 
of other proteins 







Rapid, accurate, easy to implement, can 
be compared to existing databases 
 
Enzymatic digestion with PGNase, 
Lower sensitivity, lower resolution  
Plasma HPLC-chip 
QTOF LC/MS 
Small sample volume, more informative 
than MALDI, monitoring of therapy, 
PGM1-CDG specific 
Enzymatic digestion with PGNase, 
Requires more time and expertise, 
detailed analysis and development of 
disease specific markers 
Fibroblasts MALDI 
TOF/TOF MS 
Fibroblasts can be cultured potentially 
being an indispensable source of 
sample, compared to the plasma/serum 
sample which has to be obtained 
several times and is limited in volume 
Enzymatic digestion with PGNase, 
Not validated for PGM1-CDG, 
High variability, 
Glycan profile can be influenced by 
confluency and culturing conditions 





Table 4: Molecular data of the  reported PGM1-CDG patients 
No. Publication Age (at the time of publication)/Gender  Genetic variant  Protein change  
1 Stojkovic, 2008 35 yr/ M c.343A>G  
c.1145-1G>C (intronic) 
p.Thr115Ala 
2 Timal, 2012 8 yr /M c.361G>C 
HOM 
p.Gly121Arg 




4 Perez et al, 2014 13 yr/ M c.871G>A  
c.1144 + 3A>T 
p.Gly291Arg 

















































17 Tegtmeyer et al, 2014 5 yr/ M c.184G>C 
HOM 
p.Asp62His 








20 Tegtmeyer et al, 2014 3 yr/ F c.551delT 
HOM 
p.F184Sfs*9 


















































































































48 Yokoi et al, 2018 12 yr/ M inv(1)(p31.1p32.3) 
 
- 
49 Radenkovic et al, 2019 16 yr/ F c.1508G>A 
HOM 
p.Arg503Gln 
50 Radenkovic et al, 2019 4 yr/ M c.1544G>A 
HOM 
p.Arg515Gln 
51 Radenkovic et al, 2019 6 yr/ M c.1544G>A 
HOM 
p.Arg515Gln 
52 Radenkovic et al, 2019 8 yr/ M c.1544G>A 
HOM 
p.Arg515Gln 


















57 Fernlund et al, 2019 15 yr/ M c.689G>A  
HOM 
p.Gly230Glu 
 
